Prostate-specific membrane antigen radioligand therapy of prostate cancer

被引：7
作者：
Beheshti, Mohsen [1 ,2 ]
Heinzel, Alexander [1 ]
von Mallek, Dirk [1 ]
Filss, Christian [1 ]
Mottaghy, Felix M. [1 ,3 ]
机构：
[1] RWTH Univ, Univ Hosp, Dept Nucl Med, Pauwelsstr 30, D-52074 Aachen, Germany
[2] Paracelsus Med Univ, Dept Nucl Med & Endocrinol, Salzburg, Austria
[3] Maastricht Univ, Dept Radiol & Nucl Med, Med Ctr, Maastricht, Netherlands
来源：
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 63卷 / 01期
关键词：
Prostatic neoplasms; Lu-177-PSMA-617; Radiotherapy; TARGETED ALPHA-THERAPY; RADIATION-DOSIMETRY; PSMA LIGANDS; PRECLINICAL EVALUATION; RADIONUCLIDE THERAPY; PHASE-II; BIODISTRIBUTION; INHIBITORS; PET; ANTIBODY;
D O I：
10.23736/S1824-4785.19.03155-8
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.
引用
收藏
页码：29 / 36
页数：8
相关论文
共 69 条
[1]   Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 [J].
Afshar-Oromieh, Ali ;
Haberkorn, Uwe ;
Zechmann, Christian ;
Armor, Thomas ;
Mier, Walter ;
Spohn, Fabian ;
Debus, Nils ;
Holland-Letz, Tim ;
Babich, John ;
Kratochwil, Clemens .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) :950-959
[2]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[3]   Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride [J].
Ahmadzadehfar, Hojjat ;
Zimbelmann, Stefanie ;
Yordanova, Anna ;
Fimmers, Rolf ;
Kuerpig, Stefan ;
Eppard, Elisabeth ;
Gaertner, Florian C. ;
Wei, Xiao ;
Hauser, Stefan ;
Essler, Markus .
ONCOTARGET, 2017, 8 (33) :55567-55574
[4]   Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 [J].
Ahmadzadehfar, Hojjat ;
Wegen, Simone ;
Yordanova, Anna ;
Fimmers, Rolf ;
Kuerpig, Stefan ;
Eppard, Elisabeth ;
Wei, Xiao ;
Schlenkhoff, Carl ;
Hauser, Stefan ;
Essler, Markus .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) :1448-1454
[5]   Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].
Ahmadzadehfar, Hojjat ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Fimmers, Rolf ;
Yordanova, Anna ;
Schlenkhoff, Carl Diedrich ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Essler, Markus .
ONCOTARGET, 2016, 7 (11) :12477-12488
[6]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[7]   First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer [J].
Barrett, John A. ;
Coleman, R. Edward ;
Goldsmith, Stanley J. ;
Vallabhajosula, Shankar ;
Petry, Neil A. ;
Cho, Steve ;
Armor, Thomas ;
Stubbs, James B. ;
Maresca, Kevin P. ;
Stabin, Michael G. ;
Joyal, John L. ;
Eckelman, William C. ;
Babich, John W. .
JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) :380-387
[8]   177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schuchardt, Christiane ;
Singh, Aviral ;
Wirtz, Martina ;
Wiessalla, Stefan ;
Schottelius, Margret ;
Mueller, Dirk ;
Klette, Ingo ;
Wester, Hans-Juergen .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013
[9]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
[10]   PSMA PET and Radionuclide Therapy in Prostate Cancer [J].
Bouchelouche, Kirsten ;
Turkbey, Baris ;
Choyke, Peter L. .
SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (06) :522-535
1234567